

PROXY: GENOMMA LAB INFORMS THE AMOUNT TO BE PROPOSED TO THE SHAREHOLDER'S MEETING FOR THE 2021 SHARE BUYBACK PROGRAM

Mexico City, April 14, 2021 – **Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB)** (“Genomma Lab” or “the Company”), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, informs the maximum amount to be proposed to the Annual General Shareholders Meeting, for the 2021 share buyback program. Please note that the Company has never executed the full amount authorized. Management has always been very cautious with the use of cash flow.

In accordance with section IV, Article 56 of the Mexican Securities Market Law, the maximum amount to be proposed to the shareholders meeting, which would be allocated for the repurchase of Company shares, during 2020, will be an amount equal to the balance of the total accumulated distributable net profits of Genomma Lab for the fiscal year ending on December 31, 2020, less the amount of the legal reserve as applicable.

For further understanding of the Article 56, section IV of the Mexican Securities Market Law states (Spanish Version):

Sección VI De las operaciones que las sociedades anónimas bursátiles realizan con acciones de su capital social o títulos de crédito que las representen	
Artículo 56.- Las sociedades anónimas bursátiles podrán adquirir las acciones representativas de su capital social o títulos de crédito que representen dichas acciones, sin que sea aplicable la prohibición establecida en el primer párrafo del artículo 134 de la Ley General de Sociedades Mercantiles, siempre que:	
IV.	La asamblea general ordinaria de accionistas acuerde expresamente, para cada ejercicio, el monto máximo de recursos que podrá destinarse a la compra de acciones propias o títulos de crédito que representen dichas acciones, con la única limitante de que la sumatoria de los recursos que puedan destinarse a ese fin, en ningún caso exceda el saldo total de las utilidades netas de la sociedad, incluyendo las retenidas.

For the last 3 fiscal years, the total amount invested in the share buyback program has not exceeded the total amount authorized each year by the Annual General Shareholders Meeting.

Year	Shares Repurchased	Total Investment (MXN)	% of Total Amount Authorized
2018	8,916,900	134,025,396	3.0%
2019	5,823,147	84,203,100	1.1%
2020	605,000	11,078,190	0.1%

By December 31, 2020, the total balance of the Share Buyback Program was for 36,665,792 shares representing 3.5% of total shares outstanding, with a total investment of \$229.3 million of Mexican Pesos for the last 3 fiscal years.

About Genomma Lab Internacional

Genomma Lab Internacional, S.A.B. de C.V. is one of the leading pharmaceutical and personal care products companies in Mexico with an increasing international presence. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Genomma Lab relies on the combination of a successful new product development process, a consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model. Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker **"LABB" (Bloomberg: LABB: MM)**.